Characteristic | Number | |
---|---|---|
Number of patients | N = 27 | % |
Age at enrolment (years) | Â | Â |
 Median | 59 | |
 Range | 23-80 | |
Gender | Â | Â |
 Male | 15 | 56% |
 Female | 12 | 44% |
Stage of disease at baseline | Â | Â |
 Stage IV |  |  |
 M1a | 4 | 15% |
 M1b | 4 | 15% |
 M1c | 19 | 70% |
Period of time with metastases | Â | Â |
 Median | 2.5 months | |
 Range | 0-115 months | |
LDH | Â | Â |
 Normal (≤333) | 14 | 54% |
 High (>333) | 4 | 15% |
 Unknown | 9 | 35% |
BRAF mutation | Â | Â |
 WT | 9 | 35% |
 V600E | 11 | 42% |
 V600K | 5 | 19% |
 K601E | 1 | 4% |
 unknown | 1 | 4% |
Treatment (post enrolment) | Â | Â |
 Vemurafenib | 12 | 46% |
 Ipilimumab | 4 | 15% |
 Dacarbazine | 5 | 19% |
 Surgery | 4 | 15% |
 Dabrafenib/Trametinib | 1 | 4% |
 No treatment | 1 | 4% |